Micronoma, a San Diego, CA-based early cancer-detection biotech that seeks to develop and commercializea minimally invasive, microbiome-based method, closed a $3m seed financing round.
The round was led by SymBiosis, LLC.
The company intends to use the funds to further advance cancer detection technology with the development of microbiome research, to start development work and create their CLIA (Clinical Laboratory Improvement Amendments) lab.
Incorporated in June 2019 by Sandrine Miller-Montgomery, CEO, Dr. Rob Knight, and Greg Poore, Micronoma has exclusively licensed the original IP on microbial-based cancer diagnostics and therapeutics, created by Poore and Knight, from UC San Diego. The technology has shown that distinct cancer types can be diagnosed sensitively and specifically solely using microbial nucleic acids in human blood and tissues.
While Micronoma’s method is capable of querying more than one cancer type in a single small blood sample, the company will first focus on the early detection of lung cancer.